NorCal-Gene Therapy and Research

norcaloa.com

NorCal Open Access Publications is an international open access journals publisher based at California, United States of America. All our Journals follow peer review process and publish manuscripts on an open access platform. Our Journals fall in the scope of Medical, Clinical, Life sciences, Pharmaceutical and Engineering.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

news image

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

news image

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More

Cell and Gene Therapy

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More

MedTech

QIAGEN LAUNCHES SYNDROMIC TEST FOR QIASTAT-DX DEVICE TO COMBAT GLOBAL MONKEYPOX HEALTH EMERGENCY

QIAGEN | August 16, 2022

news image

QIAGEN N.V. announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel ­– currently for research use only comes in cartridge form to run on QIAGEN’s QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus herpes simplex virus 1 HSV2, human herpesvirus 6 (HH6), varicella-zoster virus and e...

Read More
news image

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More
news image

GOLDENBIOTECH'S NEW DRUG ANTROQUINONOL RECEIVES FDA APPROVAL ON COVID-19 PHASE 2 CLINICAL TRIAL IN USA

Golden Biotechnology Corp. | July 02, 2020

Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate a...

Read More
news image

Cell and Gene Therapy

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More
news image

MedTech

QIAGEN LAUNCHES SYNDROMIC TEST FOR QIASTAT-DX DEVICE TO COMBAT GLOBAL MONKEYPOX HEALTH EMERGENCY

QIAGEN | August 16, 2022

QIAGEN N.V. announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel ­– currently for research use only comes in cartridge form to run on QIAGEN’s QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus herpes simplex virus 1 HSV2, human herpesvirus 6 (HH6), varicella-zoster virus and e...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us